Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press6310.17650/1994-4098-2013-0-3-4-86-89GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАMolecular markers of endometrial cancer (review of literature)Молекулярные маркеры рака эндометрия (обзор литературы)LevchenkoN. E.ЛевченкоН. Е.
Russian Federation
LaktionovK. P.ЛактионовК. П.
Russian Federation
TaipovM. A.ТаиповМ. А.
Russian Federation
martaip@rambler.ruTitovaM. S.ТитоваМ. С.
Russian Federation
ShevchenkoV. E.ШевченкоВ. Е.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва220920133-4868922072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/63

Currently, basic research in oncology focused on finding new potential markers of metastatic activity of tumor cells and rational approaches to cancer therapy. Constant search for biomarkers of endometrial cancer with high sensitivity and specificity, is a promising direction in medicine. Identification of new markers will identify the disease at an early stage and start early treatment.

В настоящее время фундаментальные исследования в онкологии сфокусированы на поиске новых потенциальных маркеров мета- статической активности опухолевых клеток и рациональных подходов к противоопухолевой терапии. Постоянный поиск био- маркеров рака эндометрия, обладающих высокой чувствительностью и специфичностью, является перспективным направлени- ем в медицине. Идентификация новых маркеров позволит выявлять заболевание на ранней стадии и своевременно начинать лечение.

endometrial cancerproteomicsmass spectrometrymolecular markerstargets for targeted therapyрак эндометрияпротеомикамасс-спектрометриямолекулярные маркерымишени для таргетной терапии1. Аксель Е.М. Статистика злокачественных новообразований женских половых органов. Опухоли женской репродуктивной системы 2009;(1–2):76–80.Аксель Е.М. Статистика злокачественных новообразований женских половых органов. Опухоли женской репродуктивной системы 2009;(1–2):76–80.2. Сидоренко Ю.С., Левченко Н.Е. Органо-сохраняющие и функционально-щадящие операции в онкогинекологии. Тез. докл. науч.-практ. конференции «Лечение рецидивов и метастазов злокачественных опухолей». М., 2003. С. 453–6.Сидоренко Ю.С., Левченко Н.Е. Органо-сохраняющие и функционально-щадящие операции в онкогинекологии. Тез. докл. науч.-практ. конференции «Лечение рецидивов и метастазов злокачественных опухолей». М., 2003. С. 453–6.3. Краснощекова Г.И. Современные цитологические дифференциально-диагностические критерии злокачественных опухолей тела матки. Дис. ... канд. мед. наук. М., 2005. С. 25.Краснощекова Г.И. Современные цитологические дифференциально-диагностические критерии злокачественных опухолей тела матки. Дис. ... канд. мед. наук. М., 2005. С. 25.4. Бохман Я.В. Лекции по онкогинеколо- гии. М., 2007. С. 304.Бохман Я.В. Лекции по онкогинеколо- гии. М., 2007. С. 304.5. Дубініна В.Г., Боброва В.М. Генетичні аспекти розвитку раку ендометрія. Одеський медичний журнал 2006;(3):50–7.Дубініна В.Г., Боброва В.М. Генетичні аспекти розвитку раку ендометрія. Одеський медичний журнал 2006;(3):50–7.6. Клиническая онкогинекология: Руководство для врачей. Под ред. В.П. Козаченко. М.: «Издательство Меди- цина», 2005. C. 376.Клиническая онкогинекология: Руководство для врачей. Под ред. В.П. Козаченко. М.: «Издательство Меди- цина», 2005. C. 376.7. Com E., Hondermarck H. Functional proteomics in oncology: to understand more than to describe. Med Sci (Paris) 2007;23(1):27–30.Com E., Hondermarck H. Functional proteomics in oncology: to understand more than to describe. Med Sci (Paris) 2007;23(1):27–30.8. Attarha S., Mints M., Andersson S., Souchelnytskyi S. Endometrial cancer and application of proteomics. Exp Oncol 2011;33(3):174–7.Attarha S., Mints M., Andersson S., Souchelnytskyi S. Endometrial cancer and application of proteomics. Exp Oncol 2011;33(3):174–7.9. Lawrie L.C., Fothergill J.E., Murray G.I. Spot the differences: proteomics in cancer research. Lancet Oncol 2001;2(5):270–7.Lawrie L.C., Fothergill J.E., Murray G.I. Spot the differences: proteomics in cancer research. Lancet Oncol 2001;2(5):270–7.10. Gemoll T., Habermann J.K., Lahmann J. et al. Protein profiling of genomic instability in endometrial cancer. Cell Mol Life Sci 2012;69(2):325–33.Gemoll T., Habermann J.K., Lahmann J. et al. Protein profiling of genomic instability in endometrial cancer. Cell Mol Life Sci 2012;69(2):325–33.11. Paik Y.K., Kim H., Lee E.Y. et al. Overview and introduction to clinical proteomics. Methods Mol Biol 2008;428:1–31.Paik Y.K., Kim H., Lee E.Y. et al. Overview and introduction to clinical proteomics. Methods Mol Biol 2008;428:1–31.12. Wang Y.S., Cao R., Jin H. et al. Altered protein expression in serum from endometrial hyperplasia and carcinoma patients. J Hematol Oncol 2011;4:15.Wang Y.S., Cao R., Jin H. et al. Altered protein expression in serum from endometrial hyperplasia and carcinoma patients. J Hematol Oncol 2011;4:15.13. Yokoyama T., Enomoto T., Serada S. et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer 2013;132(2):472–84.Yokoyama T., Enomoto T., Serada S. et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer 2013;132(2):472–84.14. Zhou S., Yi T., Liu R. et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012;11(7):M112.017988.Zhou S., Yi T., Liu R. et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics 2012;11(7):M112.017988.15. Alkhas A., Hood B.L., Oliver K. et al. Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue. J Proteome Res 2011;10(11):5264–71.Alkhas A., Hood B.L., Oliver K. et al. Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue. J Proteome Res 2011;10(11):5264–71.16. Yoshida A., Okamoto N., Tozawa-Ono A. et al. Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies. Hum Cell 2013;26(2):56–66.Yoshida A., Okamoto N., Tozawa-Ono A. et al. Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies. Hum Cell 2013;26(2):56–66.17. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265(2):501–23.Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265(2):501–23.18. Malle E., Sodin-Semrl S., Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66(1):9–26.Malle E., Sodin-Semrl S., Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66(1):9–26.19. Yi Z., Jingting C., Yu Z. Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells. Int J Gynecol Cancer 2009;19(3):326–33.Yi Z., Jingting C., Yu Z. Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells. Int J Gynecol Cancer 2009;19(3):326–33.20. Gao J., Niwa K., Takemura M. et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 2005;26(3):737–44.Gao J., Niwa K., Takemura M. et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 2005;26(3):737–44.21. Liang H., Cheung L.W., Li J. et al. Whole- exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012;22(11):2120–9.Liang H., Cheung L.W., Li J. et al. Whole- exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012;22(11):2120–9.22. Morin P.Jr. MiRNAs in cancer: non-coding RNAs as appealing biomarkers for malignancy. Cancer Biomark 2012;11(6):227–8.Morin P.Jr. MiRNAs in cancer: non-coding RNAs as appealing biomarkers for malignancy. Cancer Biomark 2012;11(6):227–8.23. Torres A., Torres K., Paszkowski T. et al. Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: a preliminary report. Int J Gynecol Cancer 2011;21(1):8–14.Torres A., Torres K., Paszkowski T. et al. Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: a preliminary report. Int J Gynecol Cancer 2011;21(1):8–14.24. Torres A., Torres K., Pesci A. et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013;132(7):1633–45.Torres A., Torres K., Pesci A. et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013;132(7):1633–45.25. Ramón L.A., Braza-Boïls A., Gilabert J. et al. Micro-RNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod 2012;27(10):3036–45.Ramón L.A., Braza-Boïls A., Gilabert J. et al. Micro-RNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod 2012;27(10):3036–45.26. Bae J., Won M., Kim D.Y. et al. Identification of differentially expressed microRNAs in endometrial cancer cells after progesterone treatment. Int J Gynecol Cancer 2012;22(4):561–5.Bae J., Won M., Kim D.Y. et al. Identification of differentially expressed microRNAs in endometrial cancer cells after progesterone treatment. Int J Gynecol Cancer 2012;22(4):561–5.27. Karaayvaz M., Zhang C., Liang S. et al. Prognostic significance of miR-205 in endometrial cancer. PLoS One 2012;7(4):e35158.Karaayvaz M., Zhang C., Liang S. et al. Prognostic significance of miR-205 in endometrial cancer. PLoS One 2012;7(4):e35158.28. Gilabert-Estelles J., Braza-Boils A., Ramon L.A. et al. Role of microRNAs in gynecological pathology. Curr Med Chem 2012;19(15):2406–13.Gilabert-Estelles J., Braza-Boils A., Ramon L.A. et al. Role of microRNAs in gynecological pathology. Curr Med Chem 2012;19(15):2406–13.